Latest From SRI International
The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.
Robotically assisted surgical devices are one of the hottest and fastest growing segments in the market for minimally invasive surgery (MIS) products, with a global market opportunity projected to reach more than $10 billion by 2021. A growing number of competitors hope to capture share and further expand the market by targeting key procedures and geographies with next generation robotic surgery systems and robotic-like technologies designed to improve outcomes and enable more complex procedures to be performed via an MIS approach.
Nobel Pharma Japan has entered into a license agreement with SRI International regarding the domestic clinical trials and development of SRI’s endometriosis drug candidate SR16234.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.